IFN-λ cancer immunotherapy: New kid on the block

Immunotherapy

Volumn 8, Issue 8, 2016, Pages 877-888

  Lasfar, Ahmed ^a,e   Gogas, Helen ^b   Zloza, Andrew ^c,e   Kaufman, Howard L ^c,e   Kirkwood, John M ^d  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

IFN therapy; IFN combination; IFN ; immune check point inhibitors

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CORTICOSTEROID; INTERFERON; INTERFERON LAMBDA; INTERFERON RECEPTOR; INTERLEUKIN 2; PROTEIN TYROSINE KINASE INHIBITOR; TICILIMUMAB; UNCLASSIFIED DRUG; VADIMEZAN; ANTINEOPLASTIC AGENT; IFNL4 PROTEIN, HUMAN; IL28A PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; IL29 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; T LYMPHOCYTE RECEPTOR;

ADAPTIVE IMMUNITY; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CAPILLARY HEMANGIOMA; CELL CYCLE ARREST; CHRONIC MYELOID LEUKEMIA; COLON ADENOCARCINOMA; DEPRESSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG TARGETING; FATIGUE; FLU LIKE SYNDROME; FOLLICULAR LYMPHOMA; HAIRY CELL LEUKEMIA; HUMAN; INNATE IMMUNITY; KAPOSI SARCOMA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LYMPHOCYTOPENIA; MELANOMA; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SUICIDAL IDEATION; THROMBOCYTOPENIA; TUMOR ABLATION; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT; VOMITING; ANIMAL; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; DISEASE MODEL; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; NEOPLASMS; PROCEDURES;

ADAPTIVE IMMUNITY; ANIMALS; ANTINEOPLASTIC AGENTS; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; INTERLEUKINS; MICE; NEOPLASMS;

EID: 84978954013     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2015-0021     Document Type: Review

References (98)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc. R. Soc. Lond. B. Biol. Sci. 147(927), 258-267 (1957).
2. Nagano Y, Kojima Y. [Interference of the inactive vaccinia virus with infection of skin by the active homologous virus]. C. R. Seances Soc. Biol. Fil. 152(2), 372-374 (1958).
3. Kotenko SV, Gallagher G, Baurin VV et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4(1), 69-77 (2003).
4. Sheppard P, Kindsvogel W, Xu W et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4(1), 63-68 (2003).
5. Prokunina-Olsson L, Muchmore B, Tang W et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45(2), 164-171 (2013).
6. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202, 8-32 (2004).
7. Lasfar A, Abushahba W, Balan M, Cohen-Solal KA. Interferon lambda: a new sword in cancer immunotherapy. Clin. Dev. Immunol. 2011 349575 (2011).
8. Kotenko SV. IFN-lambdas. Curr. Opin. Immunol. 23(5), 583-590 (2011).
9. Lefevre F, Guillomot M, D'Andrea S, Battegay S, La Bonnardiere C. Interferon-delta: the first member of a novel type I interferon family. Biochimie 80(8-9), 779-788 (1998).
10. Krause CD, Pestka S. Evolution of the Class 2 cytokines and receptors, and discovery of new friends and relatives. Pharmacol. Ther. 106(3), 299-346 (2005).
11. Platanias LC. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5(5), 375-386 (2005).
12. Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 32, 513-545 (2014).
13. Schoggins JW. Interferon-stimulated genes: roles in viral pathogenesis. Curr. Opin. Virol. 6, 40-46 (2014).
14. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19(21), 2468-2473 (2000).
15. Bromberg JF. Activation of STAT proteins and growth control. Bioessays 23(2), 161-169 (2001).
16. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu. Rev. Biochem. 67, 227-264 (1998).
17. Kaur S, Uddin S, Platanias LC. The PI3' kinase pathway in interferon signaling. J. Interferon Cytokine Res. 25(12), 780-787 (2005).
18. Platanias LC. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5(5), 375-386 (2005).
19. Lasfar A, Lewis-Antes A, Smirnov SV et al. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res. 66(8), 4468-4477 (2006).
20. Hamming OJ, Terczynska-Dyla E, Vieyres G et al. Interferon lambda 4 signals via the IFNlambda receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J. 32(23), 3055-3065 (2013).
21. Kotenko SV, Langer JA. Full house: 12 receptors for 27 cytokines. Int. Immunopharmacol. 4(5), 593-608 (2004).
22. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol. 29, 71-109 (2011).
23. Durbin RK, Kotenko SV, Durbin JE. Interferon induction and function at the mucosal surface. Immunol. Rev. 255(1), 25-39 (2013).
24. Hoffmann HH, Schneider WM, Rice CM. Interferons and viruses: an evolutionary arms race of molecular interactions. Trends Immunol. 36(3), 124-138 (2015).
25. Lazear HM, Nice TJ, Diamond MS. Interferon-lambda: immune functions at barrier surfaces and beyond. Immunity 43(1), 15-28 (2015).
26. Stiff A, Carson Iii W. Investigations of interferon-lambda for the treatment of cancer. J. Innate Immun. 7(3), 243-250 (2015).
27. Lasfar A, Cook JR, Cohen Solal KA et al. Critical role of the endogenous interferon ligand-receptors in type I and type II interferons response. Immunology 142(3), 442-452 (2014).
28. Pestka S. The interferon receptors. Semin. Oncol. 24(3 Suppl. 9), S9-18-S9-40 (1997).
29. Goldstein D, Laszlo J. The role of interferon in cancer therapy: a current perspective. CA Cancer J. Clin. 38(5), 258-277 (1988).
30. Gresser I, Bourali C, Levy JP, Fontaine-Brouty-Boye D, Thomas MT. Increased survival in mice inoculated with tumor cells and treated with interferon preparations. Proc. Natl. Acad. Sci. USA 63(1), 51-57 (1969).
31. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc. Natl. Acad. Sci. USA 91(4), 1198-1205 (1994).
32. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6(1), 34-55 (2001).
33. Baldo P, Rupolo M, Compagnoni A et al. Interferon-alpha for maintenance of follicular lymphoma. Cochrane Database Syst. Rev. (20(1), CD004629 (2010).
34. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. 10(5), 1670-1677 (2004).
35. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST J. Clin. Oncol. 14(1), 7-17 (1996).
36. Moschos S, Kirkwood JM. Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma. Cytokine Growth Factor Rev. 18(5-6), 451-458 (2007).
37. Moschos S, Varanasi S, Kirkwood JM. Interferons in the treatment of solid tumors. Cancer Treat. Res. 126, 207-241 (2005).
38. Kirkwood J. Cancer immunotherapy: the interferon-alpha experience. Semin. Oncol. 29(3 Suppl. 7), 18-26 (2002).
39. Kirkwood JM, Ibrahim JG, Sondak VK et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C. J. Clin. Oncol. 18(12), 2444-2458 (2000).
40. Kleeberg UR, Suciu S, Brocker EB et al. Final results of the EORTC 18871/DKG 80-1 randomised Phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur. J. Cancer 40(3), 390-402 (2004).
41. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252-264 (2012).
42. Regnier-Rosencher E, Guillot B, Dupin N. Treatments for classic Kaposi sarcoma: a systematic review of the literature. J. Am. Acad. Dermatol. 68(2), 313-331 (2013).
43. Safai B, Bason M, Friedman-Birnbaum R, Nisce L. Interferon in the treatment of AIDS-associated Kaposi's sarcoma: the American experience. J. Invest. Dermatol. 95(Suppl. 6), S166-S169 (1990).
44. Shimomura S, Ikeda N, Saito M et al. Long-term interferon therapy after radiofrequency ablation is effective in treating patients with HCV-associated hepatocellular carcinoma. Hepatol. Int. 5(1), 559-566 (2010).
45. Jiang S, Liu Y, Wang L, Duan C, Liu M. A meta-analysis and systematic review: adjuvant interferon therapy for patients with viral hepatitis-related hepatocellular carcinoma. World J. Surg. Oncol. 11, 240 (2013).
46. Mazzaferro V, Romito R, Schiavo M et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44(6), 1543-1554 (2006).
47. Saito T, Chiba T, Suzuki E et al. Effect of previous interferon-based therapy on recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int. J. Med. Sci. 11(7), 707-712 (2014).
48. Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment. Pharmacol. Ther. 32(7), 851-858 (2010).
49. Lin SM, Yu ML, Lee CM et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J. Hepatol. 46(1), 45-52 (2007).
50. Omata M, Yoshida H, Shiratori Y. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. Clin. Gastroenterol. Hepatol. 3(10 Suppl. 2), S141-S143 (2005).
51. Vezali E, Aghemo A, Colombo M. Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. Expert Opin. Biol. Ther. 11(3), 301-313 (2011).
52. Yu ML, Lin SM, Chuang WL et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir. Ther. 11(8), 985-994 (2006).
53. Ishikawa T. Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients. World J. Gastroenterol. 14(40), 6140-6144 (2008).
54. Ishikawa T, Higuchi K, Kubota T et al. Combination PEG-IFN a-2b/Ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival. Hepatogastroenterology 59(114), 529-532 (2012).
55. Gresser I, Maury C, Carnaud C, De Maeyer E, Maunoury MT, Belardelli F. Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend erythroleukemia cells. VIII. Role of the immune system in the inhibition of visceral metastases. Int. J. Cancer 46(3), 468-474 (1990).
56. Gresser I, Carnaud C, Maury C et al. Host humoral and cellular immune mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon alpha/beta treatment in mice. J. Exp. Med. 173(5), 1193-1203 (1991).
57. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13(2), 119-134 (2002).
58. Rizza P, Moretti F, Capone I, Belardelli F. Role of type I interferon in inducing a protective immune response: perspectives for clinical applications. Cytokine Growth Factor Rev. 26(2), 195-201 (2015).
59. Dunn GP, Bruce AT, Sheehan KC et al. A critical function for type I interferons in cancer immunoediting. Nat. Immunol. 6(7), 722-729 (2005).
60. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14(10), 1014-1022 (2013).
61. Rafique I, Kirkwood JM, Tarhini AA. Immune checkpoint blockade and interferon-alpha in melanoma. Semin. Oncol. 42(3), 436-447 (2015).
62. Yang X, Zhang X, Fu ML et al. Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses. Cancer Cell 25(1), 37-48 (2014).
63. Linsley PS, Speake C, Whalen E, Chaussabel D. Copy number loss of the interferon gene cluster in melanomas is linked to reduced T cell infiltrate and poor patient prognosis. PLoS ONE 9(10), e109760 (2014).
64. Fuertes MB, Woo SR, Burnett B, Fu YX, Gajewski TF. Type I interferon response and innate immune sensing of cancer. Trends Immunol. 34(2), 67-73 (2013).
65. Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin. Cancer Res. 13(18 Pt 1), 5256-5261 (2007).
66. Woo SR, Fuertes MB, Corrales L et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41(5), 830-842 (2014).
67. Ahn J, Xia T, Konno H, Konno K, Ruiz P, Barber GN. Inflammation-driven carcinogenesis is mediated through STING. Nat. Commun. 5, 5166 (2014).
68. Zhu Q, Man SM, Gurung P et al. Cutting edge: STING mediates protection against colorectal tumorigenesis by governing the magnitude of intestinal inflammation. J. Immunol. 193(10), 4779-4782 (2014).
69. Baguley BC, Ching LM. Immunomodulatory actions of xanthenone anticancer agents. BioDrugs 8(2), 119-127 (1997).
70. Lara PN Jr, Douillard JY, Nakagawa K et al. Randomized Phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J. Clin. Oncol. 29(22), 2965-2971 (2011).
71. Conlon J, Burdette DL, Sharma S et al. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J. Immunol. 190(10), 5216-5225 (2013).
72. Gao P, Ascano M, Zillinger T et al. Structure-function analysis of STING activation by c[G(2',5')pA(3',5')p] and targeting by antiviral DMXAA. Cell 154(4), 748-762 (2013).
73. Tarhini AA, Butterfield LH, Shuai Y, Gooding WE, Kalinski P, Kirkwood JM. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-alpha or TLR-9 agonist and GM-CSF with peptide vaccination. J. Immunother. 35(9), 702-710 (2012a).
74. Tarhini AA, Cherian J, Moschos SJ et al. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J. Clin. Oncol. 30(3), 322-328 (2012b).
75. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T. Antitumor activity of IFN-lambda in murine tumor models. J. Immunol. 176(12), 7686-7694 (2006).
76. Numasaki M, Tagawa M, Iwata F et al. IL-28 elicits antitumor responses against murine fibrosarcoma. J. Immunol. 178(8), 5086-5098 (2007).
77. Tezuka Y, Endo S, Matsui A et al. Potential anti-tumor effect of IFN-lambda2 (IL-28A) against human lung cancer cells. Lung Cancer 78(3), 185-192 (2012).
78. Abushahba W, Balan M, Castaneda I et al. Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol. Immunother. 59(7), 1059-1071 (2010).
79. Yan Y, Zhang J, Liu Y et al. Inhibition of lung adenocarcinoma transfected with interleukin 28A recombinant adenovirus (Ad-mIFN-lambda2) in vivo. Cancer Biother. Radiopharm. 28(2), 124-130 (2013).
80. Li Q, Kawamura K, Ma G et al. Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents. Eur. J. Cancer 46(1), 180-190 (2010).
81. Burkart C, Arimoto K, Tang T et al. Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-lambda and elevated secretion of Cxcl EMBO Mol. Med. 5(7), 967-982 (2013).
82. Souza-Fonseca-Guimaraes F, Young A, Mittal D et al. NK cells require IL-28R for optimal in vivo activity. Proc. Natl Acad. Sci. USA 112(18), E2376-E2384 (2015).
83. Li W, Lewis-Antes A, Huang J, Balan M, Kotenko SV. Regulation of apoptosis by type III interferons. Cell Prolif. 41(6), 960-979 (2008).
84. Zitzmann K, Brand S, Baehs S et al. Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochem. Biophys. Res. Commun. 344(4), 1334-1414 (2006).
85. Dumoutier L, Tounsi A, Michiels T et al. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J. Biol. Chem. 279(31), 32269-32274 (2004).
86. Hui X, Chen H, Zhang S et al. Antitumor activities of recombinant human interferon (IFN)-1 in vitro and in xenograft models in vivo for colon cancer. Cancer Lett. 311(2), 141-151 (2011).
87. Tian S, Hui X, Fan Z et al. Suppression of hepatocellular carcinoma proliferation and hepatitis B surface antigen secretion with interferon-1 or PEG-interferon-FASEB J. 28(8), 3528-3539 (2014).
88. de Groen RA, Boltjes A, Hou J et al. IFN-lambda-mediated IL-12 production in macrophages induces IFN-gamma production in human NK cells. Eur. J. Immunol. 45(1), 250-259 (2015).
89. Morrison MH, Keane C, Quinn LM et al. IFNL cytokines do not modulate human or murine NK cell functions. Hum. Immunol. 75(9), 996-1000 (2014).
90. Kirkwood JM, Bender C, Agarwala S et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J. Clin. Oncol. 20(17), 3703-3718 (2002).
91. Muir AJ, Shiffman ML, Zaman A et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 52(3), 822-832 (2010).
92. Muir AJ, Arora S, Everson G et al. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J. Hepatol. 61(6), 1238-1246 (2014).
93. Lasfar A, Abushahba W, de la Torre A, Castaneda I, Kotenko SV, Reuhl K. IFN therapy in TIB75 HCC model: combination of IFN-lambda and IFN-alpha induces complete remission. Hepatology 48(Suppl. 4), 191 (2008).
94. Duong FH, Trincucci G, Boldanova T et al. IFN-lambda receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-lambda3 genotype and with nonresponsiveness to IFN-alpha therapies. J. Exp. Med. 211(5), 857-868 (2014).
95. Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 108(10), 3253-3261 (2006).
96. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 4(3), e1000017 (2008).
97. Novak AJ, Grote DM, Ziesmer SC, Rajkumar V, Doyle SE, Ansell SM. A role for IFN-lambda1 in multiple myeloma B cell growth. Leukemia 22(12), 2240-2246 (2008).
98. Lee SJ, Lee EJ, Kim SK et al. Identification of pro-inflammatory cytokines associated with muscle invasive bladder cancer; the roles of IL-5, IL-20, and IL-28A. PLoS ONE 7(9), e40267 (2012).